Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546793 | 0.96 | BACE1 (0.39) | BACE1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL4360997 | 0.94 | BACE1 (0.37) | BACE1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL4359522 | 0.90 | BACE1 (0.39) | BACE1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL12342823 | 0.88 | MEN1 (0.38) | BACE1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL4369094 | 0.87 | ALB (0.39) | LMNAALDH1A1 | |
| SCHEMBL14342342 | 0.84 | HSD17B10 (0.35) | MEN1KMT2AP2RY12ALDH1A1ALOX15 | |
| SCHEMBL1673061 | 0.84 | HTR1A (0.37) | BACE1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL12342853 | 0.84 | MEN1 (0.37) | BACE1LMNASMN1; SMN2NPSR1MEN1 | |
| SCHEMBL1673149 | 0.83 | SLC6A9 (0.39) | ALDH1A1 | |
| SCHEMBL4363846 | 0.82 | MAOB (0.41) | LMNASMN1; SMN2NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268810-B2 | Lipophilic chelates and their use in imaging | GUERBET (FR) | 2012-09-18 | — | — | US | disclosed |
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | GUERBET (FR) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | SLC40A1, TSPO, SLC47A2 | BACE1 3350/4885LMNA 2880/4885SMN1; SMN2 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.